ScoreWhy is Fusion Antibodies Plc ?
1
Flat results in Sep 24
- OPERATING CASH FLOW(Y) Lowest at GBP -3.52 MM
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 245.24%, its profits have risen by 23.3%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Fusion Antibodies Plc for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Fusion Antibodies Plc
245.24%
3.78
87.98%
FTSE 100
15.94%
1.23
12.99%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-16.95%
EBIT Growth (5y)
-28.23%
EBIT to Interest (avg)
-1.84
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
1.42
Tax Ratio
2.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
16.07
EV to EBIT
-8.84
EV to EBITDA
-9.40
EV to Capital Employed
15.73
EV to Sales
8.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-177.90%
ROE (Latest)
-171.30%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Fusion Antibodies Plc
Net Sales
Higher at GBP 1.21 MM
than preceding 12 month period ended Sep 2024MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (GBP MM)
Operating Profit
Highest at GBP -0.73 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (GBP MM)
Pre-Tax Profit
Highest at GBP -0.79 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (GBP MM)
Pre-Tax Profit
At GBP -0.79 MM has Grown at 44.23%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (GBP MM)
Net Profit
Highest at GBP -0.76 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (GBP MM)
EPS
Highest at GBP -0.01
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (GBP)
Raw Material Cost
Fallen by -14.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Fusion Antibodies Plc
Operating Cash Flow
Lowest at GBP -3.52 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (GBP MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
